S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet
1. Regeneron Pharmaceuticals shares fell 19% after COPD treatment trial failure. 2. The failed trial did not meet primary endpoints in Phase 3. 3. Regeneron will review data and consult with regulators for next steps. 4. Sanofi, Regeneron's partner, saw a 5.7% drop in its shares. 5. S&P 500 mixed as President Trump's trade rhetoric and inflation data influenced markets.